Does the addition of venetoclax to low-dose conditioning improve outcome after allo-HSCT?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Jacqueline Garcia, Dana-Farber Cancer Institute, Boston, US. We asked, Does the addition of venetoclax to low-dose conditioning improve outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT)?

Garcia reports the results of the dose-escalation and expansion cohorts from a phase I study investigating the safety and efficacy of adding venetoclax to fludarabine and busulfan reduced intensity conditioning chemotherapy prior to allo-HSCT in patients with high-risk myeloid malignancies.